For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.
Thermo Kit Fent Rgt DRI 3x18 CJ
Thermo Kit Fent Rgt DRI 3x18 CJ
Easily reorder reagents and American-made parts.
Enjoy the fair price promise.
Take pressure off your budget (and yourself)
Product Code: 10016006
Manufacturer: Thermo Scientific
Shipping Weight: 2.00lbs (0.91kg)
Specifications
Brand: DRI®
Manufacturer: Ortho Clinical Diagnostics
Country of Origin: Canada
Application: Reagent Kit
CLIA Classification: For Forensic and Research Use Only
Container Type: Wedge
For Use With: For Clinical Chemistry Analyzers
Form: Ready-to-Use Liquid
Sample Type: Urine Sample
Storage Requirements: USP Controlled Room Temperature
Test Method: Homogenous Enzyme Immunoassay (HEIA)
Test Name: Fentanyl
Test Type: Drugs of Abuse
Volume: 3 X 18 mL
Intended Use
The DRITM Fentanyl Enzyme Immunoassay is intended for the qualitative determination of Fentanyl in human urine.
Summary and Explanation of the Test
Fentanyl is a synthetic opiate analgesic similar to morphine. Fentanyl is 50-100 times more potent than morphine. It is prescribed mainly for patients with chronic pain and is generally used to manage pain after surgery. Fentanyl is prescribed as intravenous anesthetic (Sublimaze®), transdermal patch (Duragesic®), and transmucosal Lozenge form (Actiq®). The fentanyl dose in the Duragesic ranges from 2.5-10 mg and in Actiq, it ranges from 0.2 mg-1.6 mg. The half-life of Fentanyl is 3-12 hours. Fentanyl is exclusively metabolized by N-dealkylation and hydroxylation. More than 90% of the dose is eliminated as norfentanyl and hydroxylated metabolites. Less than 7% of the dose is excreted unchanged in the urine.
The DRI Fentanyl Assay is supplied as liquid ready-to-use homogeneous enzyme immunoassay. The assay uses fentanyl specific monoclonal antibody that can detect fentanyl without any significant cross-reactivity to other opiate compounds.
The assay is based on competition between a drug labeled with glucose-6-phosphate dehydrogenase (G6PDH), and free drug from the urine sample, for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the specific antibody binds the drug labeled with G6PDH and causes a decrease in enzyme activity. This phenomenon creates a direct relationship between the drug concentration in urine and enzyme activity. The enzyme activity is determined spectrophotometrically at 340 nm by measuring the conversion of nicotinamide adenine dinucleotide (NAD) to NADH.
